

111 – AHCCCS PHARMACY AND THERAPEUTICS COMMITTEE

EFFECTIVE DATES: 04/16/19, 10/30/19, 09/01/21¹

APPROVAL DATES: 03/14/19, 10/01/19, 07/15/21²

I. PURPOSE

The AHCCCS Pharmacy & Therapeutics (P&T) Committee (Committee) is advisory to AHCCCS and is responsible for evaluating scientific evidence of the relative safety, efficacy, effectiveness, and clinical appropriateness of prescription drugs. The Committee shall make recommendations to AHCCCS on the development and maintenance of a statewide drug list and prior authorization criteria as appropriate. Committee members shall not participate in matters in which they have an actual or a potential conflict of interest and they interest. Committee members shall evaluate information regarding individual drugs and therapeutic classes of drugs in an impartial manner emphasizing the best clinical evidence and cost effectiveness consistent with Arizona Executive Order 2018-06.³

II. DEFINITIONS FOR THE PURPOSE OF THIS POLICY⁴

AHCCCS DRUG LIST A list of medications and related products supported by current evidence-based medicine. The primary purpose of the AHCCCS Drug List is to encourage the use of safe, effective, clinically appropriate medications that are also ~~and the most~~ cost-effective ~~medications~~⁵.

BUSINESS DAY A business day means a Monday, Tuesday, Wednesday, Thursday, or Friday unless a legal holiday falls on Monday, Tuesday, Wednesday, Thursday, or Friday then that day shall not be considered a business day⁶.

COMMITTEE Committee refers to tThe AHCCCS Pharmacy and Therapeutics Committee. Members of the Committee are, ~~as~~ appointed by the Chief Medical Officer (CMO) of AHCCCS or by a⁷ designee.

¹ Date changes are effective

² Date presented at APC Meeting

³ As an FYI, this policy is for the AHCCCS P&T Committee which meets a requirement for the DIR Board under Section 1927 of the Social Security Act. This section of the SSA pertains to the CMS Medicaid Pharmacy requirements. This is not in the contract between AHCCCS and the MCOs.

⁴ Added “for this policy” from a suggestion for the language.

⁵ Revised for flow

⁶ Added for clarity

⁷ Term revised for clarity

EFFECTIVENESS

The actual effects of a drug treatment under real life conditions.

EFFICACY

The ability of a treatment to achieve the desired results under ideal study conditions.

EVIDENCE-BASED MEDICINE

The judicious use of the best scientific evidence including clinical expertise and member values when making decisions about healthcare. The scientific evidence is limited to peer-reviewed articles in medical journals published in the United States.

EXECUTIVE SESSION

The Executive Session shall be held for the purpose of reviewing proprietary financial information that pertains to preferred and non-preferred drug recommendations. The Executive Sessions are confidential and are not open to the public.⁸

QUORUM

The minimum number of Committee members who must be present in order for the Committee to hold a Committee meeting and conduct business. ~~A quorum and conduct business which, for the purposes of this Policy,~~ shall be 50% of the membership plus one. ~~Because the~~ Committee is comprised of 23 members, 12 members must be present to constitute a quorum. Members who are employed by AHCCCS shall be considered for purposes of determining a Quorum.⁹

SIMPLE MAJORITY

A Simple Majority is the minimum number of Committee members that is greater than 50%. With respect to approving a motion, a simple majority of the quorum present at ~~the~~ Committee ~~meeting~~ must vote in favor of the motion in order for the motion to be approved. Members who are employed by AHCCCS shall not have voting rights and shall not be considered ~~Committee members who are AHCCCS staff do not have voting rights~~ part of the simple majority¹⁰.

III. POLICY

The Committee shall be comprised of the following¹¹ individuals as ~~described~~ specified¹² in this Policy. ~~It is the intent of AHCCCS that the Committee be comprised of members from~~

⁸ Added new definition

⁹ Added for clarity

¹⁰ Term revised for clarity

¹¹ Removed 23 and revised sentence

¹² Policy formatting; replacing with 'specified' throughout policy

~~both urban and rural areas of the State of Arizona.~~¹³

A. COMPOSITION

1. AHCCCS employees¹⁴ shall be representatives consisting of:
 - a. Chief Medical Officer (CMO) or designee,
 - b. Office of Individual and Family Affair Administrator (OIFA) or designee, and
 - c. Pharmacy Administrator or designee.

2. ~~10~~ Health care providers with active Arizona licenses in good standing and registered with AHCCCS (as applicable to the type of licensure) ~~including~~ consisting of at least one from each of the following disciplines and/or specialties (maximum of 10 members in this category)¹⁵:
 - a. Family practice,
 - b. Internal medicine,
 - c. Obstetrics and Gynecology,
 - d. Pain management,
 - e. Pediatrics,
 - f. Pharmacist,
 - g. Psychiatry, and
 - h. Registered nurse.

3. Public representatives ~~from all of the following~~ consisting of¹⁶:
 - a. Inter-Tribal Council of Arizona (ITCA),
 - b. Medicaid member, and
 - c. Medicaid member advocate.

4. AHCCCS Managed Care Organizations (MCOs) and Tribal Regional Behavioral Health Authority (TRBHA) ~~representatives~~ consisting of¹⁷:
 - a. Four MCO Medical Directors or Pharmacy Directors or their designees, and
 - b. Two TRBHA Medical Directors or Pharmacy Directors or their designees.

5. University representative consisting of¹⁸:
 - a. Researcher

B. COMMITTEE MEMBER APPOINTMENT PROCESS AND CONFLICT OF INTEREST

1. Committee members who are employed by AHCCCS ~~staff~~ shall serve continuously and are non-voting members. AHCCCS ~~staff~~ employees¹⁹ are counted for the

¹³ Removed specificity to allow for flexibility

¹⁴ Providing clarification

¹⁵ Align with policy language

¹⁶ Align with policy language

¹⁷ Align with policy language

¹⁸ Align with policy language

¹⁹ Providing clarification

purposes of determining whether or not a quorum has been met in order to proceed with the Committee meeting. The remaining Committee members shall be appointed by the AHCCCS CMO for a two- year term with the option of an additional single term renewal, for a four-year maximum.

2. Recruitment and selection of Committee member vacancies:
 - a. The AHCCCS website <https://www.azahcccs.gov/PlansProviders/Pharmacy/> provides instructions for completion of the ~~AHCCCS–P&T~~ Committee Application for Appointment and the ~~Conflict-of-Interest~~Conflict-of-Interest Disclosure Form, Attachment A, to be submitted to AHCCCS for consideration. ~~and~~
 - b. Factors considered in AHCCCS’ selection of Committee members include but are not limited ~~to:~~to the position for which they are applying, Arizona Medicaid experience, and the submitted ~~Conflict-of-Interest~~ Disclosure Form.
3. AHCCCS has the sole discretion to appoint Committee members and may terminate the appointment of any member at any time.
4. Committee members shall not:
 - a. Be employed by, subcontract with, or directly or indirectly represent a pharmaceutical manufacturer,
 - b. Be employed by, subcontract with, or directly or indirectly represent a Pharmacy Benefits Management (PBM) company, or
 - c. Receive payments or compensation from the pharmaceutical industry in excess of the CMS Open Payments database US Mean~~physician mean, including the Specialty Mean, if available, general payment amount~~²⁰ for the most recent year as specified on openpaymentsdata.cms.gov.
5. Before a Committee member participates in his/her first Committee meeting, Committee members shall submit the completed ~~Conflict-of-Interest~~ Disclosure Form and disclose any potential conflicts of interest with respect to their participation in Committee business.
6. Committee members shall update their ~~Conflict-of-Interest~~Conflict-of-Interest Disclosure Form no less than ~~annually~~12 months from the date of first completion, and additionally no later than 30 calendar days from any change to the information in the existing ~~Conflict-of-Interest~~ Disclosure Form. If a Committee meeting take place before a member can submit the form, the member shall notify the Committee of such conflict at the start of such meeting. The ~~f~~Form shall be submitted to AHCCCS at AHCCCSPharmacyDept@azahcccs.gov.
7. Committee members shall recuse themselves from any discussion, recommendation, or voting with respect to an individual drug and/or entire drug class if they have any potential conflicts^s of interest concerning the individual drug or drug class under

²⁰ Clarifying the source of the compensation

review.

8. Committee members shall complete annual conflict-of-interest training conducted by AHCCCS.

C. MEETINGS

1. The AHCCCS CMO or designee is the Committee's Chairperson and is responsible for setting meeting agendas. ~~The Committee Chairperson may call special meetings.~~ The Committee Chairperson shall preside at all meetings and shall facilitate discussion by the members.
2. The Committee shall meet virtually²¹ at least three times annually. ~~and/or at other Committee meetings may be scheduled at the discretion of times at the discretion of the Committee Chairperson or~~²² AHCCCS. Advance notice shall be provided ~~to Committee members~~ of all meetings as further detailed in this policy.
3. With the exception of the Closed Executive Session portion of the ~~the~~ Committee meetings, the ~~Committee~~ AHCCCS P&T Committee²³ meetings are open to the public. Committee meetings and the agendas are made available on the AHCCCS website: <https://www.azahcccs.gov/PlansProviders/Pharmacy/>
4. ~~A teleconference line will be available for the public portion of the meeting.~~²⁴ ~~Committee members shall physically attend all meetings in-person. Telephonic attendance by Committee members is not permitted.~~²⁵
5. ~~6.5.~~ The Executive Closed Session of the meetings²⁶ shall be held for the purpose of reviewing clinical information²⁷ and proprietary financial information that pertains to preferred and non-preferred drug recommendations. The Executive Closed Session is are confidential and is are not open to the public. ~~In addition,~~ The Committee Chairperson is responsible for calling/initiating the Executive Closed Session, which shall be limited to Committee members and the AHCCCS supplemental rebate vendor staff. Executive Closed Sessions are not ~~controlled~~ regulated by A.R.S. § 38-431.03.
7. ~~6.~~ The Committee shall:
 - a. Review the AHCCCS Drug List every two years, ~~at a minimum, biennially,~~ or on an as needed basis,
 - a.b. Review biosimilars in accordance with the AMPM Policy 310-V, and

²¹ P&T Meeting are now and in the future a virtual meeting.

²² Clarifying meeting structure

²³ Provided clarification on the executive session portion of P&T meeting

²⁴ Line removed as duplicative

²⁵ Meetings will be held virtually going forward

²⁶ Changing “closed sessions” to Executive Session since that is the terminology used on the agenda and by other states

Removing clinical²⁷

- b.c.** Review new chemical entity²⁸ drugs ~~and biosimilars~~ on or about 180 days from the date the drug is commercially available. If the new drug is a new entry to a supplemental rebate class with preferred drug(s) listed on the AHCCCS Drug List:
- i. The drug will be reviewed as a single agent if the therapeutic non-supplemental or supplemental rebate class' next review is scheduled for greater than 180 days from the date the new drug became commercially available, and
 - ii. The drug will be reviewed at the next scheduled non-supplemental/supplemental rebate class' review if the ~~supplemental rebate~~ class' next review is less than 180 days from the date the new drug became commercially available.
- e.d.** Review new drugs that are from a therapeutic class that is not currently listed as a non-supplemental/supplemental rebate class with preferred drugs on the AHCCCS Drug List in accordance with the following schedule:

NEW DRUGS COMMERCIALY AVAILABLE IN:	EXPECTED COMMITTEE MEETING FOR REVIEW:
January, February, March, or April	May
May, June, July, or August	October
September, October, November, or December	January

- d.e.** Make recommendations to AHCCCS on the grandfathering status of each non-preferred drug for each therapeutic class reviewed by the Committee, and
- e.f.** Respond to requests for medication additions, deletions, or changes to the AHCCCS Drug List submitted to AHCCCS.
- i. Requests for medication additions, deletions, or changes to the AHCCCS Drug List shall be submitted to the AHCCCS Pharmacy Department using the email address: AHCCCSPharmacyDept@azahcccs.gov and shall include the following information:
 - 1) Medication requested (brand name and generic name),
 - 2) Dosage forms, strengths, and corresponding costs of the medication requested,
 - 3) Average daily dosage,
 - 4) FDA indication and accepted off-label use,
 - 5) Advantages or disadvantages of the medication over currently available products on the AHCCCS Drug List,
 - 6) Adverse effects reported with the medication,
 - 7) Specific monitoring requirements and costs associated with these requirements, and
 - 8) For deletions, a detailed clinical summary for the request which shall also include items as specified in this Policy.

²⁸ Added chemical entity to clarify that the review is for new drugs and not new formulations of current drugs.

~~8.7.~~ On or about 60 days prior to the Committee meeting, AHCCCS shall post the therapeutic classes to be reviewed for non-supplemental and supplemental rebates on the AHCCCS website.

~~9.~~ On or about 30 days prior to the Committee meeting, the Committee members shall be provided ~~may obtain~~ clinical information for new drugs and ~~therapeutic~~ the therapeutic class reviews to be discussed at the next meeting. The clinical information²⁹ is provided by ~~from the website of~~ the AHCCCS supplemental rebate vendor., Provider Synergies., at: <http://www.providersynergies.com/services/medicaid/default.asp?content=Arizona>.

~~10.8.~~ A secure username and password may ~~is~~ be³⁰ required.

~~9.~~ On or about seven days prior to the Committee meeting AHCCCS shall:

a. Post the meeting agenda to the AHCCCS website, and

b. Provide the following to Committee member:

i. The agenda,

ii. Meeting minutes from the prior P&T meeting.

iii. Approved written public testimony, and

iv. Other materials as appropriate.

~~a.—~~

~~The Committee members will be provided an agenda and meeting materials and AHCCCS shall post on the AHCCCS website, the agenda with the list of approved speakers~~

~~11.10.~~ If a Committee member is unable to attend a meeting, the member is required to send email notification of the absence as soon as possible prior to the meeting to AHCCCSPharmacyDept@azahcccs.gov.

~~12.11.~~ Meeting minutes of the prior Committee meeting will be distributed in advance of the subsequent meeting and a formal approval process will be used to accept the minutes at the beginning of each meeting. Approved Committee meeting minutes will be posted on the AHCCCS website.

~~13.12.~~ The AHCCCS supplemental rebate vendor's clinical pharmacist and staff to present financial information³¹ ~~shall~~ may be present at the virtual meeting³² to assist the Committee Chairperson during meetings.

~~13.~~ Individuals ~~described~~ specified in Section III., G are prohibited from contacting ~~AHCCCS P&T~~ Committee members to discuss individual drugs or therapeutic classes

²⁹ Added clarifying language for the provision of clinical materials

³⁰ Removed the Vendor's name so that we do not have to update the policy with a new vendor should a change occur.

³¹ Clarifying, who must be present from the vendor to present at the meeting.

³² Clarifying the presence of the vendor's staff is virtual

to be reviewed at AHCCCS P&T Committee meetings. However, those individuals are permitted to submit written testimony as ~~described~~specified in Section III., G.

14. Approximately 30 days after³³ the AHCCCS P&T meeting date, the following documents shall be posted on the AHCCCS website:

- a. P&T presentation slides,
- b. P&T recommendation slides,
- c. Prior P&T approved meeting minutes,
- d. Accepted written public testimony,
- e. Preferred Drugs National Drug Code file, and
- a.f. Contractor P&T Meeting Summary Memo.

D. SUBCOMMITTEES

1. The AHCCCS Committee Chairperson ~~or AHCCCS~~ may designate and appoint ~~one or more~~ subcommittees.
2. A minimum of two Committee members shall serve on each such subcommittee.
3. Other persons may participate as designated by the Committee Chairperson.
4. Subcommittee members shall meet all Conflicts-of Interest requirements.
5. No subcommittee shall have authority to amend, alter, or repeal this Policy, adopt any action contrary to the Committee, or remove any member or take any action on behalf of the Committee or AHCCCS.
6. Any member of any subcommittee may be removed by the Committee Chairperson or AHCCCS whenever the best interests of the Committee or the State will be bestserved by such removal.

E. VOTING AND QUORUM

1. A quorum is necessary for the Committee to hold a meeting and transact business. A minimum of 12 of the 23 Committee members shall be present to constitute a quorum to conduct Committee business.
2. Actions of the Committee shall be transacted by motion, which may be proposed by any Committee member in attendance at the meeting. A member shall attend the meeting virtually.³⁴~~attendance,~~ Any Committee actions, including those proposed by the Committee Chairperson, ~~and~~ shall require a second. Voting on all motions shall be ~~by hand vote~~conducted electronically³⁵ unless a Committee member asks that the

³³ This section was added due to a CMS request.

³⁴ Added another virtual clarification

³⁵ Updated to electronically

roll be called and that the vote of each Committee member be recorded.

3. Voting Committee members shall have one vote on each matter submitted ~~for a to~~ vote to the Committee. Committee members who are AHCCCS staff-employees³⁶ on the Committee are non-voting members.
4. If a ~~q~~Quorum is present to conduct committee business, a ~~s~~Simple-~~m~~Majority of the voting Committee members present at the Committee meeting are required to vote in favor of a motion in order for the motion to be accepted and recommended to AHCCCS. For example, if 12 ~~C~~committee members are needed for a ~~q~~Quorum, and 17 Committee members are present, then eight Committee members who are permitted to vote are required to vote in favor of the motion in order for it to be accepted.
5. For any matter in which a Committee member has been recused from participating or acting on any matter, that Committee member shall not be counted for the purposes of determining a ~~q~~Quorum, for conducting the Committee meeting, and for determining the minimum number of votes necessary to pass a proposal related to any matter for which the Committee member has been recused. Any Committee member who has been recused shall not participate in voting with respect to the matter for which the member has been recused.
6. Committee members shall be present virtually ~~physically present, in person,~~³⁷ to vote on each matter submitted for a vote to the members.

F. PUBLIC TESTIMONY PROVIDED TO THE COMMITTEE BY INDIVIDUALS NOT SPECIFIED DESCRIBED IN SECTION III., G

1. Individuals providing oral testimony shall provide it at the virtual meeting.

~~1.2.~~ Individuals who are not Committee members and who are not ~~described-specified~~ in Section III., ~~(G)~~ are permitted to present testimony to the Committee as representatives of the public as set forth below. In order to present testimony, the representative of the public shall not be directly or indirectly employed by, contracted with, or speaking on behalf of pharmaceutical manufacturers, PBMs, lobbyists for these entities, or subcontractors of these entities.

~~2.3.~~ For individual health care providers who receive payments or compensation from manufacturers ~~that are and are~~ listed for the most recent available year in the CMS Open Payments database <https://openpaymentsdata.cms.gov>;

- a. Oral testimony is permitted if the most recent payments or compensation received by the provider on the CMS Open Payments database is equal to or less than the US Mean or the Specialty Mean for the provider.³⁸

³⁶ Providing clarification

³⁷ Replaced with virtual language to distinguish from in-person meetings.

³⁸ Providing clarification on types of testimony for a, b and c.

- b. Written testimony may only be provided when the most recent payments or compensation received by the provider ~~on the CMS Open Payments database~~ is greater than the US Mean or the Specialty Mean but less than two times the Us Mean or the Specialty Mean whichever is greater, on the CMS Open Payments database.
- c. Testimony will not be permitted for any individual health care provider, who received payments or compensation ~~for the most recent year~~ in excess of two times the US Mean or Specialty Mean, whichever is greater, ~~as reported on~~ the CMS Open Payments database.

~~Individuals, who receive payment(s) or compensation from pharmaceutical manufacturers, PBMs, or lobbyists for these entities or subcontractors of these entities, are limited to providing written testimony. Oral testimony is not permitted.~~

~~3.4. In person oral testimony by~~³⁹R representatives of the public may present oral⁴⁰ testimony virtually as set forth below:

- a. In order to present oral testimony, the individual shall be present⁴¹ ~~virtually~~ physically present at the committee meeting,

- b. The representative shall complete the Public Testimony Registration Form and the ~~Conflict of Interest~~ Conflict-of-Interest Form on the AHCCCS website at: <https://www.azahcccs.gov/AmericanIndians/Pharmacy/> ~~https://www.azahecccs.gov/PlansProviders/Pharmacy/~~ or the Provider Synergies website at: <http://www.providersynergies.com/services/medicaid/default.asp?content=Arizona> The Public Testimony Registration and the Conflict-of-Interest Forms shall be submitted to AHCCCS no later than 15⁴² business days prior to the meeting,

- c. Registration is available on a first-come, first-serve basis and shall be no more than 20 total presenters per Committee meeting. At the discretion of the Committee Chairperson, the total number of individuals who are permitted to provide oral testimony may be adjusted based on the Committee meeting agenda and time constraints,

~~b.d.~~

~~4.~~ Testimony is limited to one individual per organization, per drug, even when the organization has multiple sites.⁴³

- ~~a.e.~~ Public testimony requests from or on behalf of organizations that receive funding, grants or financial support from pharmaceutical manufacturers or entities related to pharmaceutical manufactures, shall be limited to written testimony and the request shall include the amount of grants/funding/support that has been received

³⁹ Meetings will be held virtually going forward

⁴⁰ Word smithing

⁴¹ Continuing changes for virtual meeting

⁴² Changed from 14 to 15 business days to allow 3 weeks

⁴³ Adding clarifying language because we had multiple sites submit testimony for the same drug.

from pharmaceutical manufacturers or entities related to pharmaceutical manufacturers by the organization.⁴⁴

- ~~b.~~ Individuals who present testimony shall sign in at least 10 minutes prior to the start of the meeting. Failure to do so may result in the individual not being permitted to present comments;
- ~~e.~~f. The Committee Chairperson will recognize the speakers in alphabetical order of the drugs listed in the therapeutic class being reviewed,
- ~~d.~~g. Speakers may provide comments orally at the meeting to Committee members ~~or~~ and through written testimony. ~~handouts provided to Committee members at the meeting.~~ Refer to section F. 6 for written testimony submission requirements.
- ~~e.~~h. Speakers are limited to comments that do not exceed three minutes in length per drug,
- ~~f.~~i. Questions or comments from the Committee will not be entertained unless the Committee Chairperson grants approval for questions or comments from the Committee members, and
- ~~g.~~j. The Committee Chairperson may suspend or elect to not offer the comment process for reasons including, but not limited to, speaker noncompliance with the comment process, time constraints, and/or quality of the information presented.

5. Written testimony requirements for representatives of the public as set forth below:

- ~~h.~~a. The individual requesting to provide written testimony shall complete and submit the Public Testimony Registration Form and the ~~Conflict of Interest~~ Conflict-of-Interest Form on the AHCCCS website at:
<https://www.azahcccs.gov/PlansProviders/Pharmacy/> no later than 14⁴⁵ business days prior to the meeting, and
- ~~i.~~b. Written testimony is limited to one individual per organization on each agenda item and shall not exceed two pages.

G. TESTIMONY PROVIDED TO THE COMMITTEE BY REPRESENTATIVES OF PHARMACEUTICAL MANUFACTURERS, PBMS, AND RELATED ENTITIES

1. Testimony provided to the Committee by representatives of pharmaceutical manufacturers, PBMs, and related entities is limited to written testimony. Oral testimony by these representatives is not permitted. For purposes of Section III., G, representatives are individuals who are directly or indirectly employed by, or contracted with, or speaking on behalf of pharmaceutical manufacturers, PBMs, lobbyists for these entities, or subcontractors of these entities.
2. Representatives of pharmaceutical manufacturers, PBMs, and related entities who wish to submit written clinical testimony to the Committee shall submit information to the AHCCCS Supplemental Rebate Vendor at: PSWebteam@magellanhealth.com no later than 30 business days prior to the meeting.

⁴⁴ This language is to ensure that organizations are held to the same standards as individuals

⁴⁵ Increasing from 14 days to 15 business days to allow for 3 full weeks

3. Written public testimony will not be permitted for any health care provider, representing a pharmaceutical manufacturer, PBM or a related entity, who received payments or compensation in excess of two times the US Mean or Specialty Mean, whichever is greater, as reported for the most recent available year, on the CMS Open Payments Database (openpaymentsdata.cms.gov).⁴⁶

~~All~~

3.4.All clinical information submitted shall include a one-page cover sheet that summarizes the key points and directs the Committee members to the key areas of the submitted information for consideration. Page number, paragraphs, and line numbers shall be cited.

4.5.Written content submitted by representatives of pharmaceutical manufacturers, PBMs, and related entities is limited to drugs relevant to the drug classes or individual drugs specified in the meeting agenda.

5.6.Written testimony submissions are restricted to new studies released since the last AHCCCS P&T Committee review. Testimony is limited to randomized double-blinded active control studies, and information that is published, or accepted for publication, in a peer-reviewed journal(s).

a. The following information will not be accepted:

- i. online publications,
- ii. poster presentations,
- iii. placebo controlled,
- iv. observational,
- v. open-label and non-randomized studies, or
- vi. product monographs and dossiers,
- vii. P&T Committee briefs,
- viii. extensive bibliographies, or
- ix. similar inclusions.

H. SUPPLEMENTAL REBATE OFFERS

1. The AHCCCS supplemental rebate vendor may request supplemental rebate offers from manufacturers for therapeutic class drugs, devices or other products scheduled for review at Committee meetings, upon request from AHCCCS.⁴⁷

2. Manufacturers responding to the request shall submit their offer on the *Offer Form* located on the AHCCCS supplemental rebate vendor's website.

3. Manufacturers that have a preferred drug/product on the AHCCCS Drug List may submit a new dosage formulation as a line item extension using the *Arizona Line Item Extension Form* located on the AHCCCS supplemental rebate vendor's website.

⁴⁶ Added new section for additional specificity due to Executive Order

⁴⁷ Added clarifying language

4. The following documents are also available on the AHCCCS supplemental rebate vendor’s website:
 - a. Manufacturer’s Letter Request for Supplemental Rebate Offer,
 - b. Classes and Products to be reviewed,~~and~~
 - ~~b.~~
 - c. AHCCCS P&T Committee Operational Policy,
 - d. Public Testimony Registration Form, and
 - e. Conflict-of-Interest Form.⁴⁸

I. CONTRACTS

The Committee shall not enter into contracts but may recommend that AHCCCS enter into contracts as necessary or proper to carry out the provisions and purposes of the work of the Committee.

1. Such contract(s) include but are not limited to:
 - a. engagements of independent legal,
 - b. actuarial,
 - c. clinical,
 - d. research, or
 - e. other consultants.

J. UPDATES TO THE P&T COMMITTEE OPERATIONAL POLICY

Updates to this Policy will be managed through the AHCCCS Policy Committee (APC) process.

⁴⁸ Added d. and e. to complete the list of items offered on the supplemental rebate vendor’s website.